NEUREN PHARMACEUTICALS LIMITED (NEU)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

NEU

NEU - NEUREN PHARMACEUTICALS LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: December
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: 0
Index: ASX200 | ASX300 | ALL-ORDS

Neuren Pharmaceuticals develops treatments for serious neurological and neurodevelopmental disorders.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$21.56

06 Aug
2026

-0.080

OPEN

$21.73

-0.37%

HIGH

$22.27

1,012,625

LOW

$21.02

TARGET
$26.333 22.1% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGN . ARX . ATH . AVH . BIO . BOT . COV . CSL . CUV . DXB . GSS . HXL . IDT . ILA . IMM . IMU . IVX . LGP . MAP . MSB . MVP . MYX . NUZ . OCC . OSL . PAR . PER . PNV . PYC . RAC . RCE . SNT . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
NEU: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx 23.7 41.5 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx - 78.7% 74.7% xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 54.8 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx23.7
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx64.6 M
Book Value Per Share xxxxxxxxxxxxxxx267.3
Net Operating Cash Flow xxxxxxxxxxxxxxx125.4 M
Net Profit Margin xxxxxxxxxxxxxxx47.09 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx8.67 %
Return on Invested Capital xxxxxxxxxxxxxxx8.67 %
Return on Assets xxxxxxxxxxxxxxx8.09 %
Return on Equity xxxxxxxxxxxxxxx8.67 %
Return on Total Capital xxxxxxxxxxxxxxx6.27 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx125.4 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx296 M
Price To Book Value xxxxxxxxxxxxxxx6.96

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx0.06 %
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx43 M
Research & Development xxxxxxxxxxxxxxx36 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

3
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Macquarie

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Bell Potter

06/08/2026

1

Buy

$25.50

18.27%

Bell Potter is reminded that Neuren Pharmaceuticals is eligible for a US$35m milestone payment upon first EU commercial sales of Daybue, likely in the fourth quarter of 2026. Acadia's second quarter sales were up 30% year-on-year and 23% quarter on quarter.

Acadia has lifted 2026 sales guidance to US$480m-$510m and, the broker points out, if it hits the upper end of the range, this could trigger payment to Neuren of the US$50m one-off milestone that is dependent on sales within North America exceeding US$500m in 2026.

Buy rating maintained. Target rises to $25.50 from $23.50.

FORECAST
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 34.80 cents.
Bell Potter forecasts a full year FY27 dividend of 0.00 cents and EPS of 55.40 cents.

Ord Minnett

xx/xx/xxxx

1

xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

1

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Canaccord Genuity

08/08/2026

1

Buy

$24.76

14.84%

Canaccord Genuity maintains a Buy rating for Neuren Pharmaceuticals with its target price increased to $24.76 from $24.00 following an upgraded US Daybue sales guidance from US licensing partner Acadia.

Upgraded full-year sales guidance of US$480m-US$510m for Daybue in the United States drives an increase in the broker's estimates for FY26 royalty revenues to $76.7m from $71.6m.

Commercial progress continues to be supported by strong adoption of the new powder formulation STIX, while European expansion remains on track with a planned German launch in late 2026.

The analyst values the Daybue Rett syndrome franchise at $16.03 per share, equivalent to 23.2x 2026 enterprise value to EBITDA.

Phase 3 Phelan-McDermid syndrome trial updates for NNZ-2591 in late 2027 or early 2028 represent the next major valuation inflection point for the pipeline.
Access Extra Coverage Research History >

NEU STOCK CHART

FNArena News on NEU

1
Rudi’s View: Small Cap Favourites, AI & More

Jul 16 2026 - Rudi's View
2
Australian Broker Call *Extra* Edition – Jun 30, 2026

Jun 30 2026 - Daily Market Reports
3
Australian Broker Call *Extra* Edition – May 21, 2026

May 21 2026 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – May 11, 2026

May 11 2026 - Daily Market Reports
5
Rudi’s View: Best Buys & Conviction Calls

Apr 23 2026 - Rudi's View

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Strong Result, Can Telix Continue To Deliver?

Jul 22 2026 - Australia
2
CSL Challenges Pile On, Where’s The Upside?

May 13 2026 - Australia
3
The Biotech ‘Industrialisation’

Apr 20 2026 - Small Caps
4
Telix’ Double-Product Strategy On A Roll

Apr 10 2026 - Australia
5
Focus On Telix’ Guidance Post Annus Horribilis

Jan 22 2026 - Australia
6
Anti-Vaxxers & China Cloud CSL’s Future

Oct 31 2025 - Australia
7
Rudi Interviewed: Diary Of A Successful Investor

Oct 20 2025 - Rudi's View
8
Is CSL Starting Its Price Recovery?

Sep 30 2025 - Technicals
9
Undervalued ASX Gems In Precision Medicine

Sep 23 2025 - Small Caps
10
Earnings Result Leaves CSL Bloodied

Aug 21 2025 - Australia